Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Viropharma, Inc. (NQ: VPHM)
28.69 USD  -0.18 (-0.62%)
Official Closing Price  /  Updated: 4:00 PM EDT, Jun 18, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Viropharma, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
ViroPharma Receives Orphan Drug Designation For Maribavir In Europe
June 11, 2013
from PR Newswire
ViroPharma To Participate In Several June Healthcare Investor Conferences
May 31, 2013
from PR Newswire
Regulatory Wins, Leadership Changes, and New Partnerships Creating Healthy Prospects - Research Report on Gilead, Biogen Idec, GlaxoSmithKline, Viropharma, and Celsion
May 31, 2013
from PR Newswire
Subgroup Analyses of Pivotal and Open Label Prevention Trials Showed Effectiveness of ViroPharma's Cinryze® (C1 Esterase Inhibitor [Human]) in Prevention of Angioedema Attacks in Patients with Heredit
May 28, 2013
- Oral Presentation at the 8th C1 Inhibitor Deficiency Workshop - Read More
from PR Newswire
ViroPharma To Participate In Two May Healthcare Investor Conferences
May 09, 2013
from PR Newswire
Biota Pharmaceuticals Announces Changes to Its Board of Directors
May 06, 2013
from GlobeNewswire News Releases
ViroPharma Announces First Quarter 2013 Financial Results
May 01, 2013
- Quarterly Global Cinryze® (C1 esterase inhibitor [human]) Net Sales Grew by 46 Percent to $99.5 Million - Read More
from PR Newswire
ViroPharma To Release 2013 First Quarter Financial Results On May 1, 2013
April 25, 2013
from PR Newswire
Treatment With VP20621 (Non-Toxigenic Clostridium difficile; NTCD) In A Phase 2 Study Resulted In High Rates Of Colonization And Statistically Significant Reductions In Recurrence Of C. difficile Infe
April 22, 2013
from PR Newswire
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
February 27, 2013
- Company Delivers Record Full Year Worldwide Cinryze® (C1 esterase inhibitor [human]) Net Sales of $327 Million - Read More
from PR Newswire
ViroPharma To Release 2012 Fourth Quarter And Full Year Financial Results On February 27, 2013
February 22, 2013
from PR Newswire
Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High
February 15, 2013
RDInvesting Provides Stocks Research on United Therapeutics and Viropharma Read More
from Marketwired News Releases
ViroPharma To Participate In Two Upcoming Healthcare Investor Conferences
February 11, 2013
from PR Newswire
Free Research Reports on RSYS, SNTS, VPHM and VRTX Issued by the Bedford Report
January 16, 2013
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
Sub-Group Analysis Of Data From Pediatric Patients With Hereditary Angioedema Published In The Journal Of Pediatrics
January 16, 2013
- Publication Describes Safety and Efficacy Profile of Cinryze® (C1 esterase inhibitor [human]) in Children and Adolescents Receiving 2,237 Infusions - Read More
from PR Newswire
ViroPharma Provides 2013 Outlook
January 07, 2013
- Provides 2013 Annual Net Sales Guidance of Up to $475 Million - Read More
from PR Newswire
Should Recent Insider Selling on FFIV, RHT, ALXA and VPHM Matter to You?
December 28, 2012
from Marketwired News Releases
ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2b Dose Ranging Combination Study for Subcutaneous Administration of Cinryze® (C1 esterase inhibitor [human]) With Hyaluronidase (rHuP
December 19, 2012
from PR Newswire
ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
December 12, 2012
from PR Newswire
ViroPharma To Participate In Two December Healthcare Investor Conferences
November 29, 2012
from PR Newswire
ViroPharma's Cinryze® (C1 Esterase Inhibitor [Human]) Prophylaxis Study Showed Safety Data of Escalating Doses in Patients With Hereditary Angioedema
November 13, 2012
- Safety and Efficacy of Escalating Doses Presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) - Read More
from PR Newswire
ViroPharma To Participate In Two November Healthcare Investor Conferences
November 08, 2012
from PR Newswire
ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
October 25, 2012
- Quarter Highlighted by Record U.S. Cinryze® (C1 esterase inhibitor [human]) Net Sales of $83.7M; Company Reiterates Cinryze U.S. Net Sales Guidance - Read More
from PR Newswire
Health Canada Approves New Drug Submission for Cinryze™ (C1 inhibitor [human])
October 22, 2012
- Cinryze Now Approved in Canada for Routine Prevention of Attacks of Hereditary Angioedema (HAE) - Read More
from PR Newswire
ViroPharma To Release 2012 Third Quarter Financial Results On October 25, 2012
October 18, 2012
from PR Newswire
ViroPharma Presents New Cinryze® (C1 Esterase Inhibitor [human]) Data On Site Of Care And Adherence At The 2012 Academy Of Managed Care Pharmacy Educational Conference
October 04, 2012
from PR Newswire
ViroPharma And Halozyme Provide Update On Clinical Development Of Subcutaneous Cinryze® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20)
September 21, 2012
from PR Newswire
ViroPharma To Host Analyst And Investor Seminar On September 21, 2012
September 18, 2012
from PR Newswire
ViroPharma to Present at the Stifel Nicolaus 2012 Healthcare Conference
August 30, 2012
from PR Newswire
The Shuman Law Firm Investigates ViroPharma, Inc.
August 22, 2012
from Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here